Effects of fenofibrate and gemfibrozil on plasma homocysteine

被引:70
作者
Westphal, S [1 ]
Dierkes, J [1 ]
Luley, C [1 ]
机构
[1] Otto von Guericke Univ, Inst Clin Chem & Pathobiochem, D-39120 Magdeburg, Germany
关键词
D O I
10.1016/S0140-6736(00)05271-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fenofibrate increases plasma homocysteine. Because the concentration of plasma homocysteine depends on renal function, we postulate that increases in plasma homocysteine are a result of the known impairment of renal function caused by fenofibrate. Gemfibrozil, another fibrate, does not affect renal function. In a crossover study we tested whether gemfibrozil would raise homocysteine. 22 patients who had hypertriglyceridaemia were given 900 mg gemfibrozil or 200 mg fenofibrate daily for 6 weeks. Lipids were altered similarly. but homocysteine, creatinine, and cystatin C were raised by fenofibrate but not by gemfibrozil (p for differences between treatment effects: 0.007, 0.006, and 0.040, respectively). We propose gemfibrozil should be the fibrate of choice.
引用
收藏
页码:39 / 40
页数:2
相关论文
共 5 条
[1]   Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? [J].
Broeders, N ;
Knoop, C ;
Antoine, M ;
Tielemans, C ;
Abramowicz, D .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (12) :1993-1999
[2]   Serum homocysteine increases after therapy with fenofibrate or bezafibrate [J].
Dierkes, J ;
Westphal, S ;
Luley, C .
LANCET, 1999, 354 (9174) :219-220
[3]   HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].
FRICK, MH ;
ELO, O ;
HAAPA, K ;
HEINONEN, OP ;
HEINSALMI, P ;
HELO, P ;
HUTTUNEN, JK ;
KAITANIEMI, P ;
KOSKINEN, P ;
MANNINEN, V ;
MAENPAA, H ;
MALKONEN, M ;
MANTTARI, M ;
NOROLA, S ;
PASTERNACK, A ;
PIKKARAINEN, J ;
ROMO, M ;
SJOBLOM, T ;
NIKKILA, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245
[4]  
Goffin E, 1999, LANCET, V354, P1209, DOI 10.1016/S0140-6736(05)75417-9
[5]   Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with type 2 diabetes [J].
Yoshinari, M ;
Asano, T ;
Kaori, S ;
Shi, AH ;
Wakisaka, M ;
Iwase, M ;
Fujishima, M .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1998, 42 (03) :149-154